438P Proceedings of the

The urine of male Swiss albino mice injected with [14C]-histamine (7 μg/kg) was analysed for [14C]-methylimidazoleacetic acids by gas chromatography, radioactive peaks being located as described by Robbins & Bakke (1967). Approximately 40% of the radioactivity was found in the peak corresponding to 1-MeIm4-AA, but none corresponding to 1-MeIm5-AA, thus confirming Schayer's results.

The mean 24 hr excretion of histamine and 1-MeIm4-AA in male mice during a control period of subcutaneous saline injections was 3 µg and 16 µg respectively. There was no excretion of 1-MeIm5-AA. During daily treatment with histamine (250 mg/kg subcutaneously) for 4 days the corresponding values were 3,000 μ g and 213 ug respectively, but there was still no excretion of 1-MeIm5-AA. These results, therefore, do not confirm Karjala & Turnquest's (1955) findings.

Further evidence that 1-MeIm5-AA is not a histamine catabolite was obtained during some studies on the effect of enzyme inhibitors on histamine metabolism. Under standardized dietary conditions (Granerus, 1968) a healthy adult male volunteer excreted 3.52 ± 0.07 mg 1-MeIm4-AA and 1.91 ± 0.12 mg 1-MeIm5-AA per 24 hr (mean + s.e. of mean, N=5). Treatment with transleypromine (10 mg orally every 8 hr) reduced the 24 hr excretion of 1-MeIm4-AA (2.68 ± 0.13 mg, N=3, P<0.001) but not that of the 1,5-isomer $(2.33\pm0.24 \text{ mg})$. These results support the view that methylhistamine is oxidized to 1-MeIm4-AA by monoamine oxidase in vivo, because tranylcypromine is believed to be a relatively specific inhibitor of this enzyme, and also clearly indicate that the 1-MeIm4-AA and 1-MeIm5-AA arise through different biochemical pathways. It is therefore improbable that the 1-MeIm5-AA which occurs in human urine is a metabolite of histamine formed by oxidation of 1-methyl-5-(2-aminoethyl) imidazole.

REFERENCES

Granerus, G. (1968). Urinary excretion of histamine, methylhistamine and methylimidazoleacetic acids in man under standardized dietary conditions. Scand. J. clin. Lab. Invest., 22, Suppl. 104, 59-68.

KARJALA, S. A. & TURNQUEST, B. W. (1955). The characterisation of two methylimidazoleacetic acids as radioactive histamine metabolites. J. Am. chem. Soc., 77, 6358-6359.

KELVIN, A. S. (1970). A further method of eliminating interfering compounds in the gas chromato-

graphic analysis of urinary methylimidazoleacetic acids. Br. J. Pharmac., 38, 466P.

Robbins, J. D. & Bakke, J. E. (1967). A method for collecting C¹⁴O₂ from a hydrogen flame ionisation detector. J. gas Chromat., 5, 525-526.

SCHAYER, R. (1959). Catabolism of physiological quantities of histamine in vivo. Physiol. Rev.. **39**, 116–126.

THAM, R. (1966a). Gas chromatographic analysis of histamine metabolites in urine. Quantitative determination of ring methylated imidazoleacetic acids in healthy man. J. Chromat., 23, 207-216. THAM, R. (1966b). Liberation of histamine in man. Gas chromatography of ring methylated imidazoleacetic acids in urine. Scand. J. clin. Lab. Invest., 18, 603-616.

A model noradrenaline binding site.

H. F. MARLOW (introduced by MICHAEL WARING), Department of Pharmacology, University of Stellenbosch, South Africa.

Immunoglobulins specific to noradrenaline have been prepared in rabbits by injection of a noradrenaline-bovine serum albumin complex. The immunoglobulins were extracted from the antisera by adsorption on to an insoluble polymer of the immunizing antigen with subsequent desorption by a related hapten. Complex formation between the immunoglobulin and various haptens structurally related to noradrenaline have been studied by a fluorescence quenching method. Association constants of the order of 10⁶ to 10⁷ l. mol⁻¹ were obtained for the reaction: Hapten + immunoglobulin (IgC)

IgC-hapten.